Investing.com - LumiraDx reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
LumiraDx announced earnings per share of $-0.210 on revenue of $42.22M. Analysts polled by Investing.com EPS of $-0.247 on revenue of $37.41M.
LumiraDx 's are down 28.9% and is trading at $1.115 , still down 89.94% from its 52 week high of $11.09 set on Thursday, November 18, 2021.
LumiraDx shares gained 11.60% to trade at $1.115 in intra-day trade the report.
LumiraDx follows other major Healthcare sector earnings this month
LumiraDx's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar